Watching Travere Therapeutics and CSL Vifor? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planAI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Travere Therapeutics and CSL Vifor Launch FILSPARI for IgA Nephropathy Treatment in Switzerland
SwitzerlandBiotechnologyPharmaceuticalProduct Description
Travere Therapeutics and CSL Vifor have announced that FILSPARI has received temporary marketing authorization from Swissmedic for the treatment of adults with primary IgA nephropathy, offering a once daily, oral treatment option for patients in Switzerland.
Fundz sees it the moment Travere Therapeutics and CSL Vifor ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Product Launch Insights
Based on market dataTravere Therapeutics and CSL Vifor shipped something new. Fundz reads product launches, trademark filings and hiring together.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.